Trade Aeterna Zentaris
Aeterna Zentaris Inc. is a biopharmaceutical company that markets and develops diagnostic treatments and tests. The company's lead product, Macrilen™ (Macimorelin), is the first and only US FDA and the European Commission has approved an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). McCreelin™ is currently marketed in the United States through a licensing agreement with Novo Nordisk and Eeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights in macimorelin outside the United States and Canada. Aeterna Zentaris is also taking advantage of the clinical success and convincing safety file of macimorelin for its development to diagnose the deficiency of baby growth hormone deficiency (CGHD), an area of large unmet needs. the company actively seeks business development opportunities to market macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to cash in their value.